|Day's Range||33.97 - 34.21|
|52 Week Range||29.83 - 37.39|
|PE Ratio (TTM)||28.65|
|Dividend & Yield||1.28 (3.75%)|
|1y Target Est||N/A|
It hasn't been a great year so far for Opko Health, but the future could be brighter.
On June 14, 2017, Pfizer (PFE) announced an agreement with Basilea Pharmaceutica for exclusive commercial rights for Cresemba in Europe.
After spending much of the last two months in a slow decline, shares of Pfizer have broken out of their downtrend.